

JULY 2017 PBAC MEETING – ITEMS AWAITING TGA OUTCOMES

DRUG NAME, FORM(S), STRENGTH(S), SPONSOR, TYPE OF SUBMISSION	DRUG TYPE AND USE	LISTING REQUESTED BY SPONSOR / PURPOSE OF SUBMISSION	PBAC OUTCOME
<p>METHOXSALEN</p> <p>Solution for blood fraction, 20 microgram per mL, 10 mL</p> <p>Uvadex®</p> <p>Terumo BCT Australia Pty Ltd</p> <p>New listing</p> <p>(Major Submission)</p>	<p>Erythrodermic cutaneous T-cell lymphoma</p>	<p>To request a Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listing for the treatment of patients with advanced stage, erythrodermic cutaneous T-cell lymphoma under certain conditions, as part of treatment with integrated, closed system, extracorporeal photopheresis.</p>	<p>The PBAC recommendation cannot be made public until the TGA outcome is known.</p>